Clinical Research Directory
Browse clinical research sites, groups, and studies.
Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.
Sponsor: Louisiana State University Health Sciences Center Shreveport
Summary
This study is looking to determine if Lumateperone improves motivation in patients with schizophrenia or schizoaffective disorders who show high levels of apathy as judged by AES-C-Apathy (Apathy Evaluation Scale - Clinician - Apathy) assessment and to examine a possible correlation between improvement in apathy scores and changes in elements of the PANSS (Positive and Negative Syndrome Scale) due to treatment with Lumateperone.
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2024-06
Completion Date
2026-12
Last Updated
2024-07-01
Healthy Volunteers
No
Interventions
Lumateperone 42 mg
Standard treatment with lumateperone
Risperidone 2 mg
Standard treatment with other antipsychotic drugs
Locations (1)
LSU Health Shreveport
Shreveport, Louisiana, United States